全球胰高血糖素样肽 1 (GLP-1) 激动剂市场，按药物（艾塞那肽、利拉鲁肽、度拉鲁肽、利西拉来肽）、品牌（Byetta、Bydureon、Victoza、Trulicity、Lyxumia）、给药途径（口服、肠胃外、其他）、最终用户（医院、专科诊所、其他）划分 - 行业趋势和预测到 2029 年。
市场分析和见解
胰高血糖素样肽-1 受体激动剂 (GLP-1 激动剂) 是众所周知的 2 型糖尿病有效疗法。GLP-1 RA 刺激 GLP-1 受体，从而增加胰岛素生成并减少胰高血糖素释放。尽管所有 GLP-1 RA 的作用方式相同，但它们在配方、给药、注射方法和剂量方面有所不同。目前欧洲有六种 GLP-1 RA（速释型艾塞那肽、利西拉来肽、利拉鲁肽；缓释型艾塞那肽、度拉鲁肽和索马鲁肽），每种都有自己的特点和给药要求，在日常实践中照顾患者的医生面临的挑战是了解所有这些信息，以便他们能够选择最适合患者的药物并以高效和最佳的方式使用它
胰高血糖素样肽 1 (GLP-1) 激动剂具有支持作用，旨在减轻症状的严重程度。Data Bridge Market Research 分析称，2021 年胰高血糖素样肽 1 (GLP-1) 激动剂市场价值为 125.5 亿美元，到 2029 年可能达到 201.5 亿美元，在 2022 年至 2029 年的预测期内将以 6.10% 的复合年增长率增长。
报告范围和市场细分
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020（可定制至 2019 - 2014） |
|
定量单位 |
收入（单位：十亿美元）、销量（单位：台）、定价（美元） |
|
涵盖的领域 |
药物（艾塞那肽、利拉鲁肽、度拉鲁肽、利西拉那肽）、品牌（Byetta、Bydureon、Victoza、Trulicity、Lyxumia）、给药途径（口服、肠胃外、其他）、最终用户（医院、专科诊所、其他） |
|
覆盖国家 |
北美洲的美国、加拿大和墨西哥、德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、巴西、阿根廷和南美洲其他地区 |
|
涵盖的市场参与者 |
F. Hoffmann-La Roche Ltd（瑞士）、百时美施贵宝公司（美国）、阿斯利康（英国）、辉瑞公司（美国）、百特（美国）、Hikma Pharmaceuticals plc（英国）、Amneal Pharmaceuticals, LLC（美国）、Teva Pharmaceuticals Industries Ltd（以色列）、Sun Pharmaceuticals Industries Ltd（印度）、Mylan NV（美国）、Fresenius Kabi AG（德国）。 |
|
市场机会 |
|
Glucagon-Like Peptide 1 (GLP-1) Agonists Market Dynamics
Drivers
Major factors that are expected to boost the growth of the glucagon-like peptide 1 (GLP-1) agonists market in the forecast period are as follows:
- Rise in the cases of type 2 diabetes, obesity and related disorders
The overall influence of individual-level factors, such as the population's increasing median age and health factors, such as rising obesity and inactivity rates among people, has resulted in an increase in the diabetes population over time.
- Growing adaptation of unhealthy lifestyle and genetic history of diabetes disorders
Rise in the hectic lifestyle and unbalanced food diet and the hereditary history of diabetes disorders which upsurges the danger of growing diabetes.
- The obtainability of the treatment
Growing number of middle-class households, rise in the per capita income and increasing expenditure are one of the main contributors of the market growth.
Opportunities
In addition, the enhanced healthcare infrastructure, technological developments, and the accessibility of skilled medical professionals will further provide potential opportunities for the growth of the glucagon-like peptide 1 (GLP-1) agonists market in the coming years.
Restraints/Challenges
On the flip side, strict FDA and other regulatory guidelines for the approval of new drug is further projected to impede he growth of the glucagon-like peptide 1 (GLP-1) agonists market in the timeline period. However, the dearth of suitable insurance policies might further challenge the growth of the glucagon-like peptide 1 (GLP-1) agonists market in the near future.
This glucagon-like peptide 1 (GLP-1) agonists market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on glucagon-like peptide 1 (GLP-1) agonists market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
The glucagon-like peptide 1 (GLP-1) agonists market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Covid-19 Impact on Glucagon-Like Peptide 1 (GLP-1) Agonists Market
The COVID-19 has positively affected the glucagon-like peptide 1 (GLP-1) agonists market. During the lockdowns and isolation during the pandemic complicated the diabetes management and medication adherence. Glucagon-like peptide 1 (GLP-1) agonists market promises due to its anti-inflammatory and anti-obesogenic qualities, as well as pulmonary protection and a positive impact on gut microbiota composition. Taking everything into account, glucagon-like peptide 1 (GLP-1) agonists market appear to be promising options for the treatment of COVID-19-infected patients with or without type 2 diabetes, as well as excellent antidiabetic (glucose-lowering) medications during COVID-19 pandemics.
Recent Development
- In November 2021, the Preclinical data from a series of novel dual agonists of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors was presented at ObesityWeek 2021, according to Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders.
Global Glucagon-Like Peptide 1 (GLP-1) Agonists Market Scope
The glucagon-like peptide 1 (GLP-1) agonists market is segmented on the basis of drugs, brand, route of administration and end users. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drugs
- Exenatide
- Liraglutide
- Dulaglutide
- Lixisenatide
On the basis of drugs, the glucagon-like peptide 1 (GLP-1) agonists market is segmented into exenatide, liraglutide, dulaglutide, lixisenatide.
Brand
- Byetta
- Bydureon
- Victoza
- Trulicity
- Lyxumia
On the basis of brand, the glucagon-like peptide 1 (GLP-1) agonists market is segmented into byetta, bydureon, victoza, trulicity, lyxumia.
Route of Administration
- Oral
- Parenteral
- Others
On the basis of route of administration, the glucagon-like peptide 1 (GLP-1) agonists market is segmented into oral, parenteral, others.
End Users
- Hospitals
- Specialty Clinics
- Others
On the basis of end users, the glucagon-like peptide 1 (GLP-1) agonists market is segmented into hospitals, specialty clinics, others.
Glucagon-Like Peptide 1 (GLP-1) Agonists Market Regional Analysis/Insights
The glucagon-like peptide 1 (GLP-1) agonists market is analysed and market size insights and trends are provided by country, drugs, brand, route of administration and end users as referenced above.
The countries covered in the glucagon-like peptide 1 (GLP-1) agonists market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the glucagon-like peptide 1 (GLP-1) agonists market due to the rise in the healthcare. Furthermore, the growing research and development. Furthermore, the occurrence of major key players will further boost the growth of the glucagon-like peptide 1 (GLP-1) agonists market in the region during the forecast period. Asia-Pacific projected to observe significant amount of growth in the glucagon-like peptide 1 (GLP-1) agonists market due to the rise in the incidence cases of diabetes and other related disorders. Moreover, the growing number of generic drugs is anticipated to propel the growth of the glucagon-like peptide 1 (GLP-1) agonists market in the region in the coming years.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Glucagon-Like Peptide 1 (GLP-1) Agonists Market Share Analysis
The glucagon-like peptide 1 (GLP-1) agonists market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to glucagon-like peptide 1 (GLP-1) agonists market.
胰高血糖素样肽 1 (GLP-1) 激动剂市场的一些主要参与者包括：
- 礼来（美国）
- 诺和诺德公司（丹麦）
- 阿斯利康（美国）
- 赛诺菲 (美国)
- F. Hoffmann-La Roche Ltd（瑞士）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
